Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

The role and mechanism of mesenchymal stem cells in immunomodulation of type 1 diabetes mellitus and its complications: recent research progress and challenges: a review

Wang C., Wu Y., Jiang J.

Clinical Trial on Type 1 Diabetes, Immune Modulation, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Stem Cell Res Ther (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40528233
PMCID
PMC12175325
DOI
10.1186/s13287-025-04431-1
Citations
2

Abstract (original English)

Background Mesenchymal stem cells are of great interest because of their multipotency, immune modulation capacity, and tissue and vascular regeneration effects. They are used in treating type 1 diabetes mellitus, helping improve the pancreatic environment and insulin secretion. Type 1 diabetes mellitus predominantly affects children and adolescents, with early onset and a prolonged course that can lead to multiorgan complications and related disorders. Studies using mesenchymal stem cells to treat type 1 diabetes mellitus have yielded promising results. This review discusses the common animal models of type 1 diabetes mellitus, mesenchymal stem cell immunotherapy mechanisms, and combined diabetes treatments. Its purpose is to summarize the current evidence on mesenchymal stem cell use in type 1 diabetes, providing insights for further research directions. Main findings Current studies show that mesenchymal stem cells play an active role in the treatment of type 1 diabetes; however, clinical trials remain rare, necessitating more basic and preclinical research to identify optimal treatments. Conclusions Mesenchymal stem cells can treat type 1 diabetes through a variety of immune mechanisms and also play a positive role in the treatment of type 1 diabetes complications. At the same time, it can be combined with other therapies to play a better therapeutic role.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Mesenchymal Stem CellsAnimalsHumansDiabetes Mellitus, Type 1Mesenchymal Stem Cell TransplantationImmunomodulation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research